174 related articles for article (PubMed ID: 22534075)
1. Reliability of KRAS mutation testing in metastatic colorectal cancer patients across five laboratories.
Feigelson HS; Goddard KA; Johnson MA; Funk KC; Rahm AK; Kauffman TL; Chitale DA; Le Marchand L; Richards CS
BMC Res Notes; 2012 Apr; 5():196. PubMed ID: 22534075
[TBL] [Abstract][Full Text] [Related]
2. A comparability study of 5 commercial KRAS tests.
Oliner K; Juan T; Suggs S; Wolf M; Sarosi I; Freeman DJ; Gyuris T; Baron W; Bakker A; Parker A; Patterson SD
Diagn Pathol; 2010 Apr; 5():23. PubMed ID: 20398393
[TBL] [Abstract][Full Text] [Related]
3. KRAS and BRAF mutation analysis in colorectal adenocarcinoma specimens with a low percentage of tumor cells.
Lewandowska MA; Jóźwicki W; Żurawski B
Mol Diagn Ther; 2013 Jun; 17(3):193-203. PubMed ID: 23606169
[TBL] [Abstract][Full Text] [Related]
4. Analytical performance of a PCR assay for the detection of KRAS mutations (codons 12/13 and 61) in formalin-fixed paraffin-embedded tissue samples of colorectal carcinoma.
Lee S; Brophy VH; Cao J; Velez M; Hoeppner C; Soviero S; Lawrence HJ
Virchows Arch; 2012 Feb; 460(2):141-9. PubMed ID: 22173329
[TBL] [Abstract][Full Text] [Related]
5. KRAS analysis in colorectal carcinoma: analytical aspects of Pyrosequencing and allele-specific PCR in clinical practice.
Sundström M; Edlund K; Lindell M; Glimelius B; Birgisson H; Micke P; Botling J
BMC Cancer; 2010 Dec; 10():660. PubMed ID: 21122130
[TBL] [Abstract][Full Text] [Related]
6. Comparison of COBAS 4800 KRAS, TaqMan PCR and high resolution melting PCR assays for the detection of KRAS somatic mutations in formalin-fixed paraffin embedded colorectal carcinomas.
Harlé A; Busser B; Rouyer M; Harter V; Genin P; Leroux A; Merlin JL
Virchows Arch; 2013 Mar; 462(3):329-35. PubMed ID: 23400679
[TBL] [Abstract][Full Text] [Related]
7. Metastatic colorectal cancer KRAS genotyping in routine practice: results and pitfalls.
Lamy A; Blanchard F; Le Pessot F; Sesboüé R; Di Fiore F; Bossut J; Fiant E; Frébourg T; Sabourin JC
Mod Pathol; 2011 Aug; 24(8):1090-100. PubMed ID: 21516079
[TBL] [Abstract][Full Text] [Related]
8. Detection of KRAS codon 12 and 13 mutations by mutant-enriched PCR assay.
Chang YS; Er TK; Lu HC; Yeh KT; Chang JG
Clin Chim Acta; 2014 Sep; 436():169-75. PubMed ID: 24863805
[TBL] [Abstract][Full Text] [Related]
9. Sensitive multiplex detection of KRAS codons 12 and 13 mutations in paraffin-embedded tissue specimens.
Laosinchai-Wolf W; Ye F; Tran V; Yang Z; White R; Bloom K; Choppa P; Labourier E
J Clin Pathol; 2011 Jan; 64(1):30-6. PubMed ID: 21030527
[TBL] [Abstract][Full Text] [Related]
10. High sensitivity of reverse-hybridization methodology in the detection of KRAS mutations from formalin-fixed paraffin-embedded colorectal cancer samples.
De Miglio MR; Mura A; Uras MG; Manca A; Contini M; Murgia L; Zinellu A; Sotgia S; Carru C; Massarelli G; Cossu-Rocca P
Diagn Mol Pathol; 2010 Dec; 19(4):201-8. PubMed ID: 21052001
[TBL] [Abstract][Full Text] [Related]
11. Sensitive detection of KRAS mutations in archived formalin-fixed paraffin-embedded tissue using mutant-enriched PCR and reverse-hybridization.
Ausch C; Buxhofer-Ausch V; Oberkanins C; Holzer B; Minai-Pour M; Jahn S; Dandachi N; Zeillinger R; Kriegshäuser G
J Mol Diagn; 2009 Nov; 11(6):508-13. PubMed ID: 19797612
[TBL] [Abstract][Full Text] [Related]
12. Mutation analysis of BRAF exon 15 and KRAS codons 12 and 13 in Moroccan patients with colorectal cancer.
Bennani B; Gilles S; Fina F; Nanni I; Ibrahimi SA; Riffi AA; Nejjari C; Benajeh DA; El Abkari M; Martin PM; Ouafik L
Int J Biol Markers; 2010; 25(4):179-84. PubMed ID: 21161938
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of colorectal cancer (CRC) in reference to KRAS proto-oncogene utilizing WAVE technology.
Perez K; Walsh R; Brilliant K; Noble L; Yakirevich E; Breese V; Jackson C; Chatterjee D; Pricolo V; Roth L; Shah N; Cataldo T; Safran H; Hixson D; Quesenberry P
Exp Mol Pathol; 2013 Aug; 95(1):74-82. PubMed ID: 23528430
[TBL] [Abstract][Full Text] [Related]
14. [Comparative analysis of real-time quantitative PCR-Sanger sequencing method and TaqMan probe method for detection of KRAS/BRAF mutation in colorectal carcinomas].
Zhang X; Wang Y; Gao N; Wang J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):77-82. PubMed ID: 24742565
[TBL] [Abstract][Full Text] [Related]
15. Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.
Neumann J; Zeindl-Eberhart E; Kirchner T; Jung A
Pathol Res Pract; 2009; 205(12):858-62. PubMed ID: 19679400
[TBL] [Abstract][Full Text] [Related]
16. Implementation of formalin-fixed, paraffin-embedded cell line pellets as high-quality process controls in quality assessment programs for KRAS mutation analysis.
Dijkstra JR; Opdam FJ; Boonyaratanakornkit J; Schönbrunner ER; Shahbazian M; Edsjö A; Hoefler G; Jung A; Kotsinas A; Gorgoulis VG; López-Ríos F; de Stricker K; Rouleau E; Biesmans B; van Krieken JH
J Mol Diagn; 2012; 14(3):187-91. PubMed ID: 22414609
[TBL] [Abstract][Full Text] [Related]
17. Companion-diagnostic testing limited to KRAS codons 12 and 13 misses 17% of potentially relevant RAS mutations in colorectal cancer.
Netzel BC; Grebe SK
Clin Chim Acta; 2013 Oct; 425():1-2. PubMed ID: 23832066
[TBL] [Abstract][Full Text] [Related]
18. KRAS and BRAF mutation analysis can be reliably performed on aspirated cytological specimens of metastatic colorectal carcinoma.
Pang NK; Nga ME; Chin SY; Ismail TM; Lim GL; Soong R; Salto-Tellez M
Cytopathology; 2011 Dec; 22(6):358-64. PubMed ID: 21029218
[TBL] [Abstract][Full Text] [Related]
19. The importance of evaluation of DNA amplificability in KRAS mutation testing with dideoxy sequencing using formalin-fixed and paraffin-embedded colorectal cancer tissues.
Okayama N; Nishioka M; Hazama S; Sakai K; Suehiro Y; Maekawa M; Sakamoto J; Iwamoto S; Kato T; Mishima H; Oka M; Hinoda Y
Jpn J Clin Oncol; 2011 Feb; 41(2):165-71. PubMed ID: 20926413
[TBL] [Abstract][Full Text] [Related]
20. Validation of companion diagnostic for detection of mutations in codons 12 and 13 of the KRAS gene in patients with metastatic colorectal cancer: analysis of the NCIC CTG CO.17 trial.
Harbison CT; Horak CE; Ledeine JM; Mukhopadhyay P; Malone DP; O'Callaghan C; Jonker DJ; Karapetis CS; Khambata-Ford S; Gustafson N; Trifan OC; Chang SC; Ravetto P; Iv GA
Arch Pathol Lab Med; 2013 Jun; 137(6):820-7. PubMed ID: 23030695
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
